BR0307336A - Terapia combinada do antagonista do receptor da aldosterona e do agente modulador alfa-adrenérgico para prevenção ou tratamento de condições patogênicas - Google Patents

Terapia combinada do antagonista do receptor da aldosterona e do agente modulador alfa-adrenérgico para prevenção ou tratamento de condições patogênicas

Info

Publication number
BR0307336A
BR0307336A BR0307336-0A BR0307336A BR0307336A BR 0307336 A BR0307336 A BR 0307336A BR 0307336 A BR0307336 A BR 0307336A BR 0307336 A BR0307336 A BR 0307336A
Authority
BR
Brazil
Prior art keywords
alpha
aldosterone receptor
adrenergic
receptor antagonist
treatment
Prior art date
Application number
BR0307336-0A
Other languages
English (en)
Inventor
Ellen G Mcmahon
Amy E Rudolph
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0307336A publication Critical patent/BR0307336A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TERAPIA COMBINADA DO ANTAGONISTA DO RECEPTOR DA ALDOSTERONA E DO AGENTE MODULADOR ALFA-ADRENéRGICO PARA PREVENçãO OU TRATAMENTO DE CONDIçõES PATOGêNICAS". A presente invenção refere-se a uma terapia de combinação compreendendo uma quantidade terapeuticamente eficaz de um antagonista do receptor de aldosterona e uma quantidade terapeuticamente eficaz de um agente modulador alfa-adrenérgico que é descrita para o tratamento de distúrbios circulatórios, incluindo distúrbios cardiovasculares tais como hipertensão, insuficiênica cardíaca congestiva, cirrose e ascife. Agentes moduladores alfa-adrenérgicos preferidos são aqueles compostos possuindo alta potência e biodisponibilidade. Antagonistas dos receptores de aldosterona preferidos são compostos esteroidais 20-espiroxano caracterizados pela presença de uma porção epóxi 9<244>, 11<244> substituída. Uma terapia de combinação preferida inclui um antagonista alfa 1-adrenérgico ou um agonista alfa 2-adrenérgico e o antagonista do receptor de aldosterona epoximexrenona.
BR0307336-0A 2002-01-30 2003-01-30 Terapia combinada do antagonista do receptor da aldosterona e do agente modulador alfa-adrenérgico para prevenção ou tratamento de condições patogênicas BR0307336A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35380102P 2002-01-30 2002-01-30
PCT/US2003/002723 WO2003063846A2 (en) 2002-01-30 2003-01-30 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions

Publications (1)

Publication Number Publication Date
BR0307336A true BR0307336A (pt) 2004-12-07

Family

ID=27663255

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307336-0A BR0307336A (pt) 2002-01-30 2003-01-30 Terapia combinada do antagonista do receptor da aldosterona e do agente modulador alfa-adrenérgico para prevenção ou tratamento de condições patogênicas

Country Status (11)

Country Link
US (1) US20030199483A1 (pt)
EP (1) EP1469862A2 (pt)
JP (1) JP2005519918A (pt)
KR (1) KR20040096540A (pt)
CN (1) CN1625404A (pt)
BR (1) BR0307336A (pt)
CA (1) CA2474845A1 (pt)
MX (1) MXPA04007472A (pt)
PL (1) PL371437A1 (pt)
WO (1) WO2003063846A2 (pt)
ZA (1) ZA200405437B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381163C (zh) * 2006-08-29 2008-04-16 陈俊云 一种含利美尼定的药物
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
US10350223B2 (en) 2015-03-03 2019-07-16 Richard W. Yee Compositions and methods for treating ocular diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
CA2409437A1 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
US20020123485A1 (en) * 2000-07-27 2002-09-05 Alexander John C. Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
IL162475A0 (en) * 2001-12-12 2005-11-20 Pharmacia Corp Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists

Also Published As

Publication number Publication date
WO2003063846A2 (en) 2003-08-07
JP2005519918A (ja) 2005-07-07
US20030199483A1 (en) 2003-10-23
ZA200405437B (en) 2005-07-08
MXPA04007472A (es) 2004-11-10
WO2003063846A3 (en) 2003-12-04
EP1469862A2 (en) 2004-10-27
CA2474845A1 (en) 2003-08-07
CN1625404A (zh) 2005-06-08
KR20040096540A (ko) 2004-11-16
PL371437A1 (en) 2005-06-13

Similar Documents

Publication Publication Date Title
BRPI0408362A (pt) combinação de um antagonista de receptor de aldosterona e um agente antidiabético
BR0013653A (pt) Compostos moduladores de receptores de andrógeno e progesterona bicìclicos e processos de produção e de uso
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BRPI0409617A (pt) combinação de um antagonista do receptor da aldosterona e um agente antiobesidade
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
ATE357257T1 (de) Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
TR200103104T2 (tr) Glukortikoid alıcı modülatörleri
MA33219B1 (fr) Derives d&#39;azoanthracene substitues, compositions pharmaceutiques et leurs procedes d&#39;utilisation
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
DE69531998D1 (de) Steroidrezeptor-modulator verbindungen und methoden
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
CO5261535A1 (es) Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales
ECSP034782A (es) Derivados de mercaptoacetilamida, procedimiento para su preparacion y su uso
ATE330633T1 (de) Epoxy-steroidaler aldosteronantagonist und beta- adrenergischer antagonist-kombinationstherapie zur behandlung von kongestivem herzversagen
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
NO20032261L (no) Medisinske preparater
HUP0300917A2 (hu) Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BR0307336A (pt) Terapia combinada do antagonista do receptor da aldosterona e do agente modulador alfa-adrenérgico para prevenção ou tratamento de condições patogênicas
BR0015172A (pt) Nova combinação compreendendo um agonista adreno receptor de beta 2 (beta 2) e um antagonista receptor de leucotrieno

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.